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Abstract
Objectives. PTPN22 is involved in T-cell activation and its R620W single-nucleotide polymorphism (SNP)
has been shown to predispose to different autoimmune diseases. The aims of this study were to inves-
tigate the role of the PTPN22 R620W SNP in conferring susceptibility to the ANCA-associated vasculitides
(AAVs), and to explore potential associations between the PTPN22 genotype and the disease
manifestations.
Methods. PTPN22 R620W SNP was genotyped in a cohort of 344 AAV patients [143 with granulomatosis
with polyangiitis (Wegener’s) (GPA), 102 with microscopic polyangiitis (MPA) and 99 with ChurgStrauss
syndrome (CSS)] and in 945 healthy controls.
Results. The frequency of the minor allele (620W) was significantly higher in GPA patients than in controls
[P= 0.005, 2 = 7.858, odds ratio (OR) = 1.91], while no statistically significant association was found with
MPA or CSS. Among GPA patients, the 620W allele was particularly enriched in ANCA-positive patients as
compared with controls (P= 0.00012, 2 = 14.73, OR = 2.31); a particularly marked association was also
found with ENT involvement (P= 0.0071, 2 = 7.258, OR = 1.98), lung involvement (P= 0.0060, 2 = 7.541,
OR = 2.07) and skin manifestations of all kinds (P= 0.000047, 2 = 16.567, OR = 3.73).
Conclusion. The PTPN22 620W allele confers susceptibility to the development of GPA (but not of MPA
or CSS), and particularly of its ANCA-positive subset.
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Introduction
The ANCA-associated vasculitides (AAVs) comprise a
spectrum of autoimmune diseases characterized by
necrotizing small-vessel vasculitis and the frequent pres-
ence of ANCA [1]. The AAVs include granulomatosis with
polyangiitis (Wegener’s) (GPA), microscopic polyangiitis
(MPA) and ChurgStrauss syndrome (CSS). The AAVs
range from organ-limited to disseminated, life-threatening
disorders; they commonly affect the kidney, the respira-
tory tract and the peripheral nervous system, but any
other organ or system can be involved [2]. The aetiology
of the AAVs is only partially elucidated. Infectious agents
and environmental factors are likely to play a pathogenetic
1Genetics and Molecular Biology Unit, 2Department of Clinical
Medicine and Nephrology, University Hospital, Parma, 3Department of
Life and Reproduction Sciences, Section of Biology and Genetics,
University of Verona, Verona, 4Nephrology Department, S. Maria della
Misericordia Hospital, Perugia, 5Rheumatology Unit, Arcispedale S.
Maria Nuova, Reggio Emilia, 6Internal Medicine Department, Ospedali
Riuniti, Ancona, 7Allergy and Clinical Immunology Department,
University of Torino, Torino, 8Nephrology Unit, Spedali Civili, Brescia,
9Nephrology Unit, Policlinico Hospital, Milano, 10Pulmonology Unit,
University of Milano Bicocca, Monza, 11Nephrology and Clinical
Immunology Unit, San Carlo Borromeo Hospital, Milano, 12Nephrology
Unit, Legnano Hospital, Legnano, 13Nephrology Unit, S. Anna Hospital,
Como, 14Internal Medicine Department, Arcispedale S. Maria Nuova,
Reggio Emilia and 15Respiratory Pathophysiology Unit, University
Hospital, Parma, Italy.
Correspondence to: Augusto Vaglio, Dipartimento di Clinica Medica e
Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci
14, 43126 Parma, Italy. E-mail: augusto.vaglio@virgilio.it
Submitted 18 July 2011; revised version accepted 1 December 2011.
! The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com 1
RHEUMATOLOGY
B
A
S
IC
S
C
IE
N
C
E
 Rheumatology Advance Access published January 11, 2012
 by guest on January 12, 2012
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
role [35], but genetic determinants are also claimed to
increase susceptibility to the development of AAVs [69].
However, as the AAVs have different clinical phenotypes,
it is plausible that their genetics also differs [4, 5, 9];
thus, genetic studies on the AAVs need to include
patients with all the three AAV forms to investigate
potential similarities or differences in their genetic
background.
Genetic risk factors may be disease specific, but some
of them may be common determinants of a wide range
of conditions, particularly in the setting of autoimmunity
[10]. This is the case of the gene encoding protein
tyrosine phosphatase type 22 (PTPN22), whose R620W
single-nucleotide polymorphism (SNP) [rs2476601,
NM_015967.5(PTPN22_v001): c.1858C>T] has been
described as a common genetic risk factor for many auto-
immune and inflammatory diseases [1114]. PTPN22
encodes a lymphoid-specific phosphatase (LYP); the
R620W SNP, causing substitution of arginine for trypto-
phan at amino acid residue 620, has been shown to affect
proteinprotein interactions between LYP and the tyrosine
kinase Csk, which is involved in T-cell activation.
Furthermore, a role in B-cell signalling has also been sug-
gested [15].
The role of the PTPN22 R620W polymorphism in the
AAVs has been explored in a German cohort of GPA
patients [16] and in a UK cohort comprising patients
with all AAVs [6]. Both studies demonstrated that it is a
susceptibility factor for GPA, and the UK study also found
a significant association with MPA. However, the potential
association between this SNP and CSS has not been ana-
lysed; in addition, the association found with MPA
resulted from the analysis of a relatively small cohort of
patients (only 74 patients in the UK study had a known
diagnosis of MPA), and has never been replicated in other
populations. Finally, the association between genetic and
clinical findings was only investigated in the German
study.
In the present study we genotyped the PTPN22 R620W
polymorphism in a cohort of 344 AAV patients (including
GPA, MPA and CSS) and in 945 healthy controls, in order
to replicate its association with GPA and MPA and to
explore whether it also confers susceptibility to CSS.
Additionally, we also investigated potential associations
between this SNP and the main clinical manifestations
of AAVs or their disease patterns.
Patients and methods
Study subjects
We recruited 344 consecutive patients with AAV
[175 women and 169 men, with a median age at diagnosis
of 55 (range 1386) years]. The patients were recruited at
the following centres in northern Italy: the Nephrology
Departments of the University Hospitals in Parma and
Brescia, of the Policlinico and San Carlo Borromeo
Hospitals in Milano, and of the general hospitals in
Perugia, Legnano and Como; the Rheumatology
Department of Reggio Emilia Hospital; the Pulmonary
Department of the Milano Bicocca University Hospital;
and the Internal Medicine Departments of the Reggio
Emilia Hospital and of the University Hospitals in Torino
and Ancona.
One hundred and forty-three patients were affected by
GPA, 102 by MPA and 99 by CSS. The AAVs were diag-
nosed based on the presence of clinical manifestations
consistent with small-vessel vasculitis, with or without
histological confirmation, then the diseases were classi-
fied as GPA, MPA or CSS following the 1990 ACR classi-
fication criteria for CSS and GPA, and the Chapel Hill
Consensus Conference definitions [1719]. When a diag-
nostic biopsy was not available and ANCAs were negative
or undetermined, the diagnosis had to be supported by a
compatible clinical picture, together with surrogate mark-
ers for GPA (i.e. persistent lung infiltrates, nodules or cavi-
tations, bronchial stenosis, bloody nasal discharge or
crusting, retro-orbital mass, chronic rhino-sinusitis, otitis
or mastoiditis, saddle nose deformity, subglottic stenosis)
or renal vasculitis (i.e. haematuria with red cell casts or 2+
haematuria and 2+ proteinuria) [20]; in cases of suspected
CSS, at least four of the five non-histological ACR criteria
had to be fulfilled. As examples, patients with chronic
sinusitis and crusts, lung nodules and rapidly progressive
renal failure with an active urinary sediment were included
as GPA cases, whereas patients with only lung nodules
and rapidly progressive renal failure but without active
urinary sediment were excluded; equally, patients with
asthma, eosinophilia, neuropathy and lung infiltrates
were included as CSS cases, whereas patients with only
asthma, eosinophilia and lung infiltrates were excluded.
Patients with rapidly progressive renal failure but without
involvement of other organs were excluded despite the
presence of an active urinary sediment because it was
not possible to classify them [20]. Importantly, in patients
with negative or undetermined ANCA and no diagnostic
biopsy, we required a minimum follow-up of 6 months for
diagnosis confirmation.
Organ involvement in the AAV patients was assessed
by physical examination, routine laboratory tests and a
standardized set of imaging studies. ANCA status was
determined at the time of diagnosis using IIF and anti-
gen-specific PR3 and MPO ELISAs.
A total of 945 age- and gender-matched healthy
subjects with no history of autoimmune or inflammatory
diseases served as controls. All the study subjects were of
Italian Caucasian origin and, similar to the cases, they all
came from northern Italy. Individuals from genetic isolates
were not included.
Written informed consent was obtained from all
subjects included in the study, and from parents for
minors as appropriate. The study was conducted in
accordance with the Declaration of Helsinki. The study
was approved by the Ethical Committees of the
University Hospital of Parma, Perugia Hospital, Reggio
Emilia Hospital, Ospedali Riuniti in Ancona, University of
Torino, Spedali Civili in Brescia, Policlinico and San Carlo
Borromeo Hospitals in Milano and Milano Bicocca
University.
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SNP genotyping
Genomic DNA was extracted from EDTA-treated periph-
eral blood samples (5 ml of blood per study subject) using
the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA,
USA) and stored at 20C until use. The rs2476601
PTPN22 SNP was genotyped using an ABI PRISM 7700
Sequence Detector (Applied Biosystems, Foster City, CA,
USA) with a TaqMan 50-allele discrimination Assay-
By-Design method (Applied Biosystems, Foster City, CA,
USA). PCR was performed according to the manufactur-
er’s instructions. In order to confirm TaqMan genotyping,
one-third of the samples were sequenced with a Sanger-
based method (CEQ 2000XL Sequence Analysis,
Beckman Coulter, CA, USA). The primer sequences
used to confirm the TaqMan genotypes were as follows:
forward, 50-ATGAGCCACCATGCCCAT-30; reverse: 50-AT
GTTGCTTCAACGGAATTTAAAT-30.
Statistical analysis
Association analysis between the R620W polymorphism
and each of the phenotypes investigated was performed
by allelic test. Furthermore, the association with the three
AAV phenotypes (GPA, MPA, CSS) was also investigated
using a dominant model for the allele 620W, as suggested
by other authors [16].
Multiple testing was treated using the severe
Bonferroni’s correction as follows. The three AAV pheno-
types were investigated using the allelic and dominant
models, and correction was applied for the five tests per-
formed for each of the two models (Table 1). The threshold
for defining an association significant when five tests are
computed is Pcor = 0.01, in accordance with Bonferroni’s
correction, and thus an association was defined statistic-
ally significant when its nominal P-value was lower than
Pcor = 0.01. It is noteworthy that this correction is some-
what too severe since the five tests for each model are not
independent.
Association was also investigated for 14 clinical and
laboratory characteristics correlated with the AAV pheno-
types. A total of 14 tests was computed and an associ-
ation was defined as significant when its nominal P-values
were <0.0036. Statistical analyses were performed using
the software PLINK v1.07 (http://pngu.mgh.harvard.edu/
purcell/plink/index.shtml).
Results
Clinical characteristics and laboratory findings of the
patients
The main clinical and laboratory characteristics of the en-
rolled AAV patients are shown in Table 2. Detailed clinical
data were available in 336 (97.7%) of the 344 patients. In
the remaining eight patients (two with GPA, four with MPA
and two with CSS), the clinical diagnosis was entered by
the recruiting clinician into the study database; however,
given the lack of a complete clinical phenotyping, all of
these cases had to have a positive PR3- or MPO-ANCA
test as well as a diagnostic biopsy to be included. The
percentages of the clinical manifestations reported T
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hereafter are calculated out of the number of patients in
whom a given manifestation or laboratory test was
available.
GPA was the most common diagnosis (42%).
Constitutional symptoms (e.g. fatigue, fever, anorexia,
weight loss) were found in 121 (87.7%) patients.
Seventy-eight per cent of the patients exhibited ENT
involvement. Lung involvement was another major clinic
manifestation, affecting 96 (68%) patients, 26 of whom
had alveolar haemorrhage. Renal involvement was found
in 94 (67%) patients and a rapidly progressive glomerulo-
nephritis (RPGN) occurred in 60 (43%) cases. Skin mani-
festations were found in 35 (25%) patients, 19 of whom
had purpura. Peripheral neuropathy occurred in 32 (23%)
patients, with 12 exhibiting mononeuritis multiplex.
MPA was diagnosed in 102 (30%) patients. Renal
involvement was the most frequent clinical manifestation,
affecting 91 (92%) cases, 71 of whom had RPGN.
Nineteen (19%) patients had a renal-limited form of
MPA, whereas the remaining 71% had a systemic disease
with different vasculitic manifestations, especially periph-
eral neuropathy (28%), ENT and lung involvement (33 and
53%, respectively), and skin manifestations (14%).
Ninety-nine (29%) patients were affected by CSS.
Asthma, ENT involvement and peripheral neuropathy
were the major clinical manifestations, affecting
90 (93%), 84 (87%) and 75 (77%) patients, respectively.
Constitutional symptoms were found in 71 (73%) cases.
Lung involvement occurred in 50 (52%) patients, only 4 of
whom had alveolar haemorrhage. Forty-three per cent of
the patients exhibited skin manifestations, with purpura in
14% of the cases. Renal involvement occurred in
27 (29%) patients; only three patients had RPGN.
Gastrointestinal, cardiac and CNS manifestations
occurred in 13 (13%), 16 (17%) and 7 (7%) patients with
CSS, respectively.
ANCAs were positive by IF in 227 (80.5%) patients with
AAV, negative in 51 (14.8%) and undetermined in
16 (4.7%). The cANCA pattern was more frequent in
GPA (80% of the patients), whereas pANCA predomi-
nated in MPA and CSS patients (87 and 53%, respective-
ly). ELISA showed anti-PR3 antibodies in 78% of the
tested GPA cases, whereas 89% of the tested MPA and
54% of the tested CSS cases had anti-MPO antibodies.
A diagnostic biopsy was available in 217 (63%) patients,
of whom 105 had GPA, 39 had CSS and 73 had MPA.
Thirty-six patients, of whom 28 had CSS and 8 had GPA,
had no diagnostic biopsy and negative or undetermined
ANCA; however, all of these patients had a typical clinical
phenotype and, in those classified as GPA, surrogate
markers of GPA or renal vasculitis [20].
Overall, this collection of patients has a clinical pheno-
type comparable with that of other large published series
[21, 22] and probably reflects the true presentation of
AAVs, given the multidisciplinary nature of the recruiting
centres.
PTPN22 rs2476601 genotyping in AAV
The genotype frequencies of both AAV patients and
healthy controls were in HardyWeinberg equilibrium.
TABLE 2 Demographic and clinical features of the 344 patients with ANCA-associated vasculitides
GPA (n=143) MPA (n=102) CSS (n=99) All (n=344)
Mean age at disease onset (range), years 51 (1385) 61 (1683) 53 (1886) 55 (1386)
Male/female, n 73/70 46/56 50/49 169/175
Cardiovascular involvement 11/141 (7.8) 11/98 (11.2) 16/97 (16.5) 38/336 (11.3)
Cutaneous involvement, all kinds 35/141 (24.8) 14/98 (14.3) 42/97 (43.3) 91/336 (27.1)
Purpura 19/141 (13.5) 6/98 (6.1) 14/97 (14.4) 39/336 (11.6)
Gastrointestinal involvement 4/141 (2.8) 7/98 (7.1) 13/97 (13.4) 24/336 (7.1)
Peripheral neuropathy, all kinds 32/141 (22.7) 27/98 (27.6) 75/97 (77.3) 134/336 (39.9)
Mononeuritis multiplex 12/141 (8.5) 10/98 (10.2) 36/97 (37.1) 58/336 (17.3)
CNS involvement 10/141 (7.1) 3/98 (3.1) 7/97 (7.2) 20/336 (5.9)
Eye involvement 32/141 (22.7) 5/98 (5.1) 7/97 (7.2) 44/336 (13.1)
ENT involvement 111/141 (78.7) 32/98 (32.7) 84/97 (86.6) 227/336 (67.5)
Lung involvement, all kinds 96/141 (68.1) 52/98 (53.1) 50/97 (51.5) 198/336 (58.9)
Alveolar haemorrhage 26/139 (18.7) 21/98 (21.4) 4/97 (4.1) 51/334 (15.3)
Asthma 6/141 (4.3) 8/98 (8.2) 90/97 (92.8) 104/336 (31.0)
Constitutional symptomsa 121/138 (87.7) 80/98 (81.6) 71/97 (73.2) 272/333 (81.7)
Renal involvement, all kinds 94/141 (66.7) 91/99 (91.9) 27/93 (29.0) 212/333 (63.7)
RPGN 60/139 (43.2) 71/99 (71.7) 3/92 (3.3) 134/330 (40.6)
Mean serum creatinine (range), mg/dl 2.9 (0.814.6) 4.2 (0.517.9) 1.0 (0.56.2) 2.8 (0.817.9)
Proteinuria >1 g/24 h 41/115 (35.7) 54/87 (62.1) 7/81 (8.7) 102/283 (36.0)
pANCA by IF 29/139 (20.9) 86/99 (86.9) 48/90 (53.3) 163/328 (49.7)
cANCA by IF 111/139 (79.8) 8/99 (8.1) 7/90 (7.8) 126/328 (38.4)
Anti-MPO antibodies 16/113 (14.2) 75/84 (89.3) 22/41 (53.7) 113/238 (47.5)
Anti-PR3 antibodies 93/120 (77.5) 6/81 (7.4) 0/40 (0) 99/241 (41.1)
Except where indicated otherwise, values are the n (%) of patients. aFatigue, fever, anorexia and weight loss.
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Table 1 shows the PTPN22 rs2476601 genotype and allele
frequencies in AAV patients and healthy controls.
Genotype analysis was not performed because the num-
bers in most categories were too small. The frequency of
the minor allele (620W) was higher in GPA patients than in
controls [P= 0.0051, 2 = 7.858, odds ratio (OR) = 1.91],
whereas no statistically significant differences were
found in its frequency between CSS patients (P= 0.1508,
2 = 2.065, OR = 0.51), MPA patients (P= 0.1072,
2 = 2.595, OR = 1.59) and controls.
When we compared the frequency of the 620W allele
between all AAV patients (GPA + MPA + CSS) and healthy
controls, the difference was not statistically significant
(P= 0.0729, 2 = 3.216, OR = 1.40). Conversely, when
GPA and MPA were grouped together, the difference in
allele frequency vs healthy controls was even more pro-
nounced (P= 0.0031, 2 = 8.718, OR = 1.78) than if GPA
alone was considered.
We also performed a meta-analysis (Supplementary
Table S1, available as supplementary data at
Rheumatology Online) combining our results on GPA
and MPA cases with those of the previous two studies
[6, 16]; this reinforced the strength of the association be-
tween the rare allele and AAV, although its significance is
limited by the fact that the German study only included
GPA cases and that the UK study did not provide the
allelic frequencies of the single AAV subtypes (GPA and
MPA).
We also tested the hypothesis of a dominant model for
the allele 620W since other authors suggested a dominant
effect of this allele in GPA patients [16]. We confirmed the
association between the R620W polymorphism and GPA
(P= 0.0095, 2 = 6.72, OR = 1.91) and we also observed a
significant association when GPA and MPA patients were
grouped together (P= 0.0034, 2 = 6.72, 8.563, OR = 1.83).
No association was found when CSS patients were tested
alone or grouped with GPA and MPA patients.
We next analysed AAV patients with respect to their
ANCA status (with ANCA status being determined by IF):
a statistically significant difference was found between
ANCA-positive (either pANCA, cANCA or P + C) AAV pa-
tients and healthy controls (P= 0.00813, 2 = 7.005,
OR = 1.65). When we only considered ANCA-positive
GPA patients (Table 3), the association with the SNP
was highly pronounced, with a P-value (P= 0.00012,
2 = 14.73, OR = 2.31) more significant than that obtained
when all GPA patients were considered. Furthermore, the
predisposing allele was more frequent in GPA patients
with anti-PR3 antibodies (P= 0.02319, 2 = 5.154,
OR = 1.88). Overall, PTPN22 620W was more frequent in
all AAV patients with anti-PR3 antibodies than in controls
(P= 0.0088, 2= 6.848, OR = 2.00), whereas the associ-
ation with anti-MPO antibodies did not reach statistical
significance (P= 0.131).
PTPN22 R620W SNP association with organ
involvement in GPA patients
Further analyses of this polymorphism focused on its
association with organ involvement in GPA patients,
as shown in Table 3. The 620W allele was predominantly
associated with skin involvement (P= 0.000047,
2 = 16.567, OR = 3.73), lung involvement (P= 0.0060,
2 = 7.541, OR = 2.07), ENT manifestations (P= 0.0071,
2 = 7.258, OR = 1.98) and constitutional symptoms
(P= 0.0098, 2 = 6.665, OR = 1.90). Interestingly, despite
the strong enrichment in GPA patients with skin involve-
ment, the 620W allele frequency was not increased in
TABLE 3 Organ involvement, ANCA status and the PTPN22 R620W polymorphism in GPA patients
GPA Controls GPA Controls
P-valuea OR (95% CI)
genotypes
WW/WR/RR
genotypes
WW/WR/RR
number of
alleles, W/R
number of
alleles, W/R
Cardiovascular 0/1/10 4/82/859 1/21 90/1800 0.9622 0.952 (0.127, 7.159)
Skin, all kinds 0/11/24 4/82/859 11/59 90/1800 0.000047b 3.729 (1.894, 7.343)
Purpura 0/4/15 4/82/859 4/34 90/1800 0.1023 2.353 (0.817, 6.774)
Peripheral
neuropathy
0/7/25 4/82/859 7/57 90/1800 0.0253 2.456 (1.089, 5.538)
ENT 2/16/93 4/82/859 20/202 90/1800 0.0071 1.98 (1.194, 3.284)
Lung, all kinds 2/14/80 4/82/859 18/174 90/1800 0.0060 2.069 (1.218, 3.513)
Alveolar
haemorrhage
0/6/20 4/82/859 6/46 90/1800 0.0262 2.609 (1.086, 6.268)
Constitutional
symptoms
1/19/101 4/82/859 21/221 90/1800 0.0098 1.9 (1.158, 3.118)
Kidney, all kinds 1/15/78 4/82/859 17/171 90/1800 0.0113 1.988 (1.157, 3.417)
ANCA 3/23/114 4/82/859 29/251 90/1800 0.00012b 2.311 (1.49, 3.584)
pANCA 1/7/21 4/82/859 9/49 90/1800 0.00024b 3.673 (1.75, 7.712)
cANCA 2/16/93 4/82/859 20/202 90/1800 0.0071 1.98 (1.194, 3.284)
Anti-MPO 0/5/11 4/82/859 5/27 90/1800 0.0049 3.704 (1.394, 9.843)
Anti-PR3 1/14/78 4/82/859 16/170 90/1800 0.0231 1.882 (1.081, 3.277)
OR indicates the effect of the minor allele 620W compared with the allele 620R. aSignificance of association based on the
allelic test. bAssociation statistically significant also after correction for multiple tests.
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those with purpura as compared with controls (P= 0.1023,
2 = 2.669, OR = 2.35); purpura is typically due to
leucocytoclastic vasculitis. We reviewed the available
skin biopsies to ascertain whether non-purpuric le-
sions actually showed granulomatous inflammation.
Thirty-five patients with GPA had skin lesions: of these,
19 had purpura. Skin biopsy was performed in 8 of the 19
patients with purpura (showing in all of them typical
leucocytoclastic vasculitis) and in 5 of the 16 patients
with non-purpuric lesions; 4 of these 5 cases had
histological features consistent with granulomatous in-
flammation, with or without associated histological signs
of vasculitis.
Only weak associations were found between the
R620W SNP and other disease manifestations in which
organ damage is due to small-vessel vasculitis, such as
kidney involvement and peripheral neuropathy (Table 3).
Taken together, these findings (especially the marked
association with ENT, lung and non-purpuric skin involve-
ment) seem to point towards a particular association
between the PTPN22 R620W SNP and the granulomatous
manifestations of GPA. We also examined the potential
associations between this SNP and the main dis-
ease manifestations or disease subsets of MPA and
CSS (e.g. renal-limited or systemic MPA, vasculitic or
non-vasculitic CSS) [7, 23, 24], but found no significant
differences in allele and genotype frequencies in compari-
son with controls. Also, there was no association with the
ENT-limited or generalized forms of GPA.
Discussion
PTPN22 is located on chromosome 1p13.313.1 and
encodes an 807-amino acid residue protein also referred
to as LYP, which interacts with the tyrosine kinase Csk in
the intracellular signalling cascade following T-cell activa-
tion [25]. The autoimmunity-predisposing allele of PTPN22
is a missense C>T variation at position 1858, which
changes the amino acid residue 620 from arginine (R) to
tryptophan (W) in the encoded LYP protein. The PTPN22
R620W substitution results in a gain of enzymatic function
that increases the threshold for TCR signalling. This SNP
also seems to impair B-cell signalling in a way that is simi-
lar to that demonstrated for T cells [15]. How an impaired
amplification of TCR signalling may predispose to the de-
velopment of autoimmunity remains unclear. Two theories
have been postulated: the first is based on the relevance
of thymic selection as a mechanism for establishing pre-
disposition to autoimmune diseases. In the thymus, the
increase in TCR signalling threshold caused by the
PTPN22 R620W SNP can lead to positive selection of
thymocytes that would otherwise undergo deletion, with
resulting appearance of autoreactive T cells in the periph-
ery. The second theory instead involves regulatory T cells,
which under physiological conditions are thought to limit
the emergence of autoimmunity. An impaired TCR signal-
ling involving particularly the regulatory T-cell compart-
ment may eventually boost autoimmunity [26, 27].
The PTPN22 620W allele was previously found to be
associated with type 1 diabetes (T1D) [28, 29], RA
[3032], JIA [3335], SLE [29, 36, 37], Graves’ disease
[38], myasthenia gravis [39] and generalized vitiligo as
well as with AAV [16, 40, 41]. The association with other
autoimmune disorders (e.g. SS, SSc) is controversial.
Interestingly, some autoimmune conditions (e.g. Crohn’s
disease) are associated with the alternative allele (R620)
[42]. A recent meta-analysis confirmed that T1D, RA, JIA,
SLE and Graves’ disease were associated with the 620W
allele, while multiple sclerosis, IBD, psoriasis and
Addison’s disease were not [13]. Based on these results,
PTPN22 appears to predispose particularly to autoim-
mune conditions characterized by circulating auto-
antibodies [26, 27].
The results of our study confirm the previously demon-
strated association between the PTPN22 R620W SNP and
GPA [6, 16]; in opposition to the findings obtained by the
UK study [6], we failed to demonstrate any association
with MPA. Additionally, this SNP did not seem to confer
susceptibility to CSS. Our results, however, are difficult to
compare with those obtained by the UK and German stu-
dies: the UK study was performed on a larger cohort of
AAV patients, but only a small part of them had a clinical
diagnosis of either GPA or MPA; moreover, this study was
not intended to explore associations between genetic and
clinical findings [6]. On the other hand, the German study
provided detailed clinical and laboratory findings, but only
included GPA patients [16].
GPA, MPA and CSS are often grouped under the um-
brella term AAVs because of their common association
with ANCA, but they have profound differences in clinical
and epidemiological characteristics. This makes it likely
that they also have distinct genetic backgrounds. Only a
few of the gene polymorphisms studied (e.g. CD226) were
shown to be common genetic risk factors for the different
AAVs [43], whereas most associations with variants of pu-
tative autoimmunity genes were restricted to single forms
(e.g. CTLA4 in GPA, IL10 in ANCA-negative CSS) [44, 45];
the HLA variants associated with the different AAVs also
differ (e.g. HLA-DPB1 in GPA and HLADR4 in CSS) [8, 24].
As already pointed out in the German study [16], we
also found that the association with the PTPN22 SNP
was stronger for ANCA-positive GPA than for the whole
GPA population; this is in line with the hypothesis that
PTPN22 R620W SNP mainly predisposes to autoimmune
diseases with circulating autoantibodies.
In the present study, a careful clinical characterization
of the patients allowed the investigation of genotyp-
icphenotypic associations. In the German study [16],
the 620W allele was particularly associated with kidney,
lung, eye and peripheral nervous system involvement. We
instead found that this allele was enriched predominantly
in GPA patients with ENT and lung involvement, and skin
lesions other than purpura, whereas the association with
kidney and peripheral nervous system involvement was of
borderline significance. While these differences may be
accounted for by the small size of the patient subgroups
or by differences in clinical phenotyping, our results seem
to point to a particular association between the PTPN22
SNP and a granulomatous disease pattern of GPA. As a
6 www.rheumatology.oxfordjournals.org
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matter of fact, ENT lesions in GPA are typically granu-
lomatous [46], and so are usually the lung ones (with the
exception of alveolar haemorrhage, which was not strik-
ingly associated with the 620W allele); skin lesions may be
granulomatous or vasculitic, but one of the most typical
vasculitic manifestations (i.e. purpura) was again not
associated with the 620W allele.
Interestingly, PTPN22 is thought to be involved in
granuloma formation in GPA [47]. GPA is believed to
arise as an aberrant cell-mediated immune response to
microbial pathogens (e.g. Staphylococcus aureus) colo-
nizing the upper airway tract; this probably leads to the
formation of granulomata and ectopic lymphoid struc-
tures, which may promote the breakdown of tolerance
towards PR3 and the subsequent formation of
PR3-ANCA [3, 47, 48]. PTPN22 is thought to be involved
in the exuberant response mediated by T cells, which re-
lease pro-inflammatory cytokines (e.g. IFN-g, TNF-a) able
to induce macrophage recruitment and granuloma forma-
tion [16, 47, 48]. In vivo data also support this view, as
mice lacking Pep (the murine orthologue of PTPN22) dis-
play enhanced expansion and function of the effect-
or/memory T-cell pool and spontaneous germinal centre
formation [49]. However, further studies are needed to
confirm our findings and to clarify whether the PTPN22
R620W SNP actually predisposes to a particular GPA
phenotype. In conclusion, the results of the present
study confirm that the PTPN22 620W allele is a genetic
risk factor for the development of GPA (but not of MPA or
CSS) and particularly of its ANCA-positive subset.
Rheumatology key messages
. The PTPN22 R620W SNP is a susceptibility factor
for the development of GPA.
. The PTPN22 R620W SNP is not associated with
susceptibility to develop MPA or CSS.
. The ANCA-positive subset of GPA is strongly asso-
ciated with the PTPN22 R620W SNP.
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